The patent for Xerese (acyclovir and hydrocortisone) is set to expire in February 2016. Until the patent expires, Xerese is protected from generic competition in the United States. However, lawsuits or other factors could extend or shorten this exclusivity period. Once the exclusivity period expires, several companies could start making a generic version.
Xerese™ (acyclovir and hydrocortisone) is a prescription medication approved for the treatment of cold sores. It combines acyclovir, an antiviral medicine, with hydrocortisone, a corticosteroid that can reduce inflammation. Xerese comes in the form of a cream that is applied to the cold sore.
Xerese is made by Contract Pharmaceuticals Limited for Meda Pharmaceuticals, Inc. It is currently under the protection of a patent that prevents any generic versions of the medication from being manufactured in the United States.
The first patent for Xerese currently expires in February 2016. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to extend or shorten the exclusivity period. This could include such things as lawsuits or other patents for specific Xerese uses. Once the patent expires, there may be several companies that manufacture a generic Xerese drug.
No -- acyclovir and hydrocortisone are the active ingredients in Xerese, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.